USD 80 Million Pharma Manufacturing Facility to Be Built in Saudi
The facility, which will be built by Abu Dhabi’s Julphar, will support the Kingdom’s efforts to reduce imported medications.
Gulf Pharmaceutical Industries (Julphar), listed on the Abu Dhabi stock exchange, has announced plans to invest SAR 300 million in a new pharmaceutical and biotech manufacturing facility in Saudi Arabia. The project will focus on the production of complex biologics, sterile formulations, and general medications, adhering to strict international quality standards.
Construction is expected to begin in the first quarter of 2025, with the facility aiming to produce a range of advanced treatments upon completion. Julphar's new site will enhance local pharmaceutical production capabilities, supporting the Kingdom’s efforts to strengthen its healthcare sector and reduce reliance on imported medications.
The facility looks to contribute to the development of the regional pharmaceutical industry by creating jobs and fostering innovation in drug manufacturing. It also aligns with Saudi Arabia’s broader industrial growth goals, particularly as the country seeks to increase self-sufficiency in critical sectors.
